Table 1.
Patient characteristics
| Characteristics | Total cohort (N = 14) | Dara/dex (N = 7) | Dara/dex + additional treatment (N = 7) |
|---|---|---|---|
| Sex male/female, n (%) | 9 (64.3)/5 (35.7) | 5 (71.4)/2 (28.6) | 4 (57.1)/3 (42.9) |
| Age, median (range) | 66.2 (47.8-80.9) | 71.8 (49.0-80.7) | 62.7 (47.8-80.3) |
| ECOG (0/1 versus ≥ 2), n (%) | 11 (78.6) versus 3 (21.4) | 4 (57.1) versus 3 (42.9) | 7 (100.0) versus 0 (0.0) |
| Involved free light chain, n (%) | |||
| Kappa | 2 (14.3) | 0 (0.0) | 2 (28.6) |
| Lambda | 12 (85.7) | 7 (100.0) | 5 (71.4) |
| Staging Mayo 2004, n (%) | |||
| I | 1 (7.1) | 1 (14.3) | 0 (0.0) |
| II | 4 (28.6) | 2 (28.6) | 2 (28.6) |
| IIIa | 7 (50.0) | 2 (28.6) | 5 (71.4) |
| IIIb | 2 (14.3) | 2 (28.6) | 0 (0.0) |
| Staging Mayo 2012, n (%) | |||
| I | 2 (14.3) | 1 (14.3) | 1 (14.3) |
| II | 2 (14.3) | 1 (14.3) | 1 (14.3) |
| III | 3 (21.4) | 1 (14.3) | 2 (28.6) |
| IV | 7 (50.0) | 4 (57.1) | 3 (42.9) |
| Plasma cells in bone marrow (%), median (range) | 15 (5-30) | 15 (5-20) | 20 (7-30) |
| Patients with ≥10% plasma cells, n (%) | 12 (85.7) | 6 (85.7) | 6 (85.7) |
| Number of organs involved, median (range) | 2 (1-4) | 2 (1-4) | 2 (1-4) |
| Number of organs involved ≥2, n (%) | 9 (64.3) | 4 (57.1) | 5 (71.4) |
| Number of organs involved ≥3, n (%) | 2 (14.3) | 1 (14.3) | 1 (14.3) |
| Organ involvement, n (%) | |||
| Heart | 11 (78.6) | 6 (85.7) | 5 (71.4) |
| Kidney | 9 (64.3) | 4 (57.1) | 5 (71.4) |
| Nervous system | 3 (21.4) | 1 (14.3) | 2 (28.6) |
| Gastrointestinal | 2 (14.3) | 1 (14.3) | 1 (14.3) |
| Other | 2 (14.3) | 1 (14.3) | 1 (14.3) |
| Lab parameters at diagnosis | |||
| Involved FLC level, median (range) | 277.5 (106-2960) | 297 (114-2960) | 258 (106-984) |
| dFLC (mg/dl), median (range) | 250.2 (21-2924.4) | 276.9 (100.6-2924.4) | 223.5 (21-954.6) |
| Patients with dFLC ≥180 mg/l, n (%) | 8 (57.1) | 4 (57.1) | 4 (57.1) |
| NT-pro-BNP (pg/ml), median (range)a | 3385 (387.3-177 668.0) | 4994 (387.3-17 768.0) | 3385 (1251-6245) |
| Troponin T (ng/ml), median (range)a | 73 (16-244) | 112 (16-244) | 73 (53-112) |
| Protein-to-creatinine ratio (mg/g), median (range)a | 3934.0 (123-9412) | 3613.5 (123-5393) | 5712 (701-9412) |
Dara/dex, daratumumab and dexamethasone; dFLC, difference in involved and uninvolved free light chains; NT-pro-BNP, N-terminal pro–B-type natriuretic peptide.
a
Only values for patients with the respective organ affected are given.